Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (4946)	7/22/1998 11:53:00 AM
From: Timothy Kross	of 6136

I have been an Agouron shareholder for a number of years. The present price weakness is an excellent opportunity to dollar cost average more shares into the portfolio. In essence, there is nothing that will replace PIs in the AIDS armamentarium in the near future. I believe the only thing that will do them in is drug resistance in the HIV naive patient. The July 20th issue of AMA News, page 52, has an article on treatment of HIV. A physician survey by Louis Harris and associates indicates that many people are not being treated presently with state of the art triple drug therapy that include a PI, and two NRTIs. They are recommending an HIV specialty board to assure that present treatment guidelines are being met. It appears that there will be many cases of AIDS that were treated with one or two drugs, not including PIs. This means that when they relapse, there will room for PIs because they will be PI naive. This could be an excellent market for PIs and Sustiva. Best regards. Tim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next